Group infant nutrition revenue came to $659.2m, up 33.1 per cent.
There was strong growth in China label infant nutrition, with sales doubling to $146.7m.
READ MORE:
• Premium - A2 Milk chair says Jayne Hrdlicka's departure was not performance-related
• Premium - Big Read: A2 Milk - formula for growth
• Premium - Creaming it: a2 Milk's steady rise to the top
• Premium - A2 Milk result: Poised for first-half profit lift, coronavirus clouds outlook
A2 Milk said it was unable to quantify the impact, either positively or negatively, of the coronavirus outbreak in China.
For the full 2020 year, the company said it anticipated continued strong revenue growth across its key regions supported by increased marketing investment in China and in the US.
"Globally, there is uncertainty around the potential impact to supply chains and consumer demand in China resulting from Covid-19 and we continue to monitor the situation closely," the company said.
"Given the essential nature of our products for many Chinese families, demand is strong, particularly through online and reseller channels, with revenue for the first two months of 2H20 above expectations," a2 Milk said.
"However, this is a dynamic situation and at this stage, we are unable to quantify the impact, either positively or negatively, for the full year," it said.
Notwithstanding this uncertainty, full-year EBITDA margin was still anticipated to be in the range of 29-30 per cent - unchanged from its previous guidance.
A2 Milk added that the board "considered it appropriate" to target EBITDA margin of 30 per cent in the medium term.
The company said that given the Covid-19 situation, it was assessing the level of discretionary marketing investment deployed in China for the remainder of the year.
The company's share price rallied by 77c, or 5.5 per cent, to $16.55, in the minutes following the result.
